HeartSciences reports no Q2 revenue, $2M cash; submits wavECG to FDA

HeartSciences Inc.

2025-Q2 EPS reported -$2.10 revenue$4,319

No meaningful revenue for FQ2 2026; cash and equivalents $2.0M, shareholders' equity $4.2M as of Oct 31, 2025.
MyoVista wavECG device submitted to FDA for 510(k) clearance, a key regulatory milestone.
MyoVista Insights software platform (MDDS, exempt from 510(k)) launched May 2025; V1.1 released; commercial discussions underway.
Company plans investor call early 2026 to demonstrate MyoVista Insights software and provide commercialization strategy.
Algorithms for LVDD assessment separated from device submission due to updated ASE guidelines.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.